From heat-related illness to mosquito-borne infections, physicians are seeing the effects of a warming planet in the exam room. There's a growing push to teach doctors-in-training how to respond.
In Libby, Mont., an estimated 1 in 10 have an asbestos-related illness, after decades of pollution from a now-shuttered mine. With lungs already scarred, many fear contracting the coronavirus.
Members of Congress and advocacy groups say Operation Warp Speed should release its contracts with vaccine makers after NPR reporting found the terms of many aren't public.
The use of an immune-system stimulant harvested from shark liver oil in the development of some coronavirus vaccines has animal conservationists pressing for alternatives.
Trump's physician said Trump could resume "public engagements" as soon as Saturday. But experts say that may be too soon, both for his own health and the safety of those around him.
Medical researchers have high hopes that the kind of treatment the president received could end up being an important element in the fight against the pandemic. But clinical trials continue.
Coughs, sore throats and runny noses are common in fall and winter, and they rarely signal dire disease. But with COVID-19 a threat this year and flu an annual hazard, here's what you need to know.
Large-scale safety and efficacy trials of experimental vaccines in tens of thousands of volunteers are underway. Answers about the trials are likely to come late this year.
President Trump will continue to get top-of-the-line medical care for COVID-19 now that he's back at the White House, including the final dose of the new antiviral medication, remdesivir
The requirements laid out by the Food and Drug Administration in advice for drugmakers underscore why it's unlikely a vaccine could clear the agency before Election Day.
Some public health experts hope the growing availability of faster, cheaper tests could lead to a new strategy of widespread testing — one that could finally get the pandemic under control.
More than $6 billion in federal funding has been routed through a firm that manages defense contracts, making the agreements subject to less federal scrutiny and transparency.
California will be the first state to create its own line of generic drugs to cope with high drug prices. A new law lets the state outsource manufacturing but control pricing and distribution.
